BAFNAPH — Bafna Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- IN₹2.01bn
- IN₹2.23bn
- IN₹1.52bn
- 27
- 34
- 25
- 14
R2020 March 31st | 2021 March 31st | R2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 425 | 712 | 851 | 1,154 | 1,525 |
Cost of Revenue | |||||
Gross Profit | 154 | 258 | 339 | 389 | 456 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 445 | 654 | 808 | 1,035 | 1,464 |
Operating Profit | -20.4 | 58.2 | 43.1 | 119 | 61.1 |
Total Net Non Operating Interest Income / Expense | |||||
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -18.8 | 58.3 | 52.2 | 116 | 73.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -18.8 | 58.3 | 52.2 | 113 | 73.5 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -252 | 58.3 | 52.2 | 113 | 73.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -252 | 58.3 | 52.2 | 113 | 73.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -7.94 | 2.46 | 3.1 | 4.78 | 3.11 |